Latest Commercialisation News

OncoSil Medical has launched a $8.7 million capital raising via a Share Purchase Plan and Placement, seeking shareholder approval for options issuance and a 400:1 share consolidation.

Bass Oil Limited reported steady April production and a strategic acquisition of the Vanessa gas field, positioning itself for future gas market entry.

State Gas Limited faces a land access blockade at its Rolleston West Project, prompting legal action to resume critical drilling operations. The dispute threatens to delay progress on promising coal seam gas assets in Queensland's Bowen Basin.

Jade Gas Holdings has completed Mongolia’s inaugural horizontal coal bed methane wells at the Red Lake field, setting the stage for initial gas production by early June 2025. The company is advancing commercial partnerships to leverage this milestone for cleaner energy solutions in the South Gobi region.

Rhythm Biosciences has successfully validated its second-generation ColoSTAT® Beta assay, confirming its readiness for commercial application in colorectal cancer detection. The Beta kit offers improved precision and faster turnaround times compared to its predecessor.

McLaren Minerals has completed its Phase 1 drilling program at the McLaren Titanium Project, revealing significant extensions to its mineral sands resource and setting the stage for future growth.

South Africa’s Minister of Mineral Resources has upheld Renergen’s helium extraction rights at the Virginia Gas Project, rejecting an appeal from Springbok Solar and securing the company’s production future.

Proteomics International has validated its PromarkerEndo blood test as a highly accurate, non-invasive diagnostic tool for endometriosis, with commercial launch planned in Australia for Q3 2025. The test promises to reduce the average seven-year diagnostic delay by providing a simple risk score applicable across all disease stages.

GreenHy2 Limited has broadened its renewable energy storage portfolio by integrating graphene-based hybrid supercapacitor batteries, reporting robust FY24 growth and advancing key customer trials.

EBR Systems has announced a fully underwritten A$55.9 million capital raise alongside a Security Purchase Plan to fund the commercial rollout of its FDA-approved WiSE CRT System, targeting a US$3.6 billion market opportunity in cardiac resynchronization therapy.

EBR Systems has raised A$55.9 million through a fully underwritten placement to fund the commercial rollout of its FDA-approved wireless cardiac pacing system, with plans for a limited market release in H2 2025 and expanded distribution in 2026.

AFT Pharmaceuticals reported a 6% revenue increase to NZ$208 million in FY25, driven by strong ANZ growth and expanding international presence. The company targets NZ$300 million revenue by FY27 amid ongoing R&D and new product launches.